Literature DB >> 8822934

Presence in peripheral blood of healthy individuals of autoreactive T cells to a membrane antigen present on bone marrow-derived cells.

M C Filion1, C Proulx, A J Bradley, D V Devine, R P Sékaly, F Décary, P Chartrand.   

Abstract

Intrathymic clonal deletion is thought to be the major mechanism responsible for tolerance to nonsequestered antigens such as the ones expressed by bone marrow-derived cells. In the case of sequestered antigens that potentially do not come in contact with T cells in the thymus, it is thought that autoreactive T cells are present in periphery but are tightly regulated to prevent autoimmune disease. Indeed, autoreactive T cells to sequestered antigens can be isolated in healthy individuals. However, the presence of autoreactive T cells to nonsequestered circulating antigens had not been observed. In this report, we present evidence for the presence, in the periphery of all healthy individuals tested (n = 25), of autoreactive T cells to GpIIb-IIIa, a membrane antigen present on bone marrow-derived cells that is expressed on circulating platelets and on the cell surface of the epithelial cells of the thymic stroma early in intrauterine life. Using an in vitro T-cell proliferation assay, we have demonstrated that activation of these specific GpIIb-IIIa autoreactive alpha beta TCR+ CD4+ CD8- T cells requires internalization and processing of the GpIIb-IIIa by antigen-presenting cells and its presentation by HLA-DR class II molecules in the presence of exogenous interleukin 2 (IL-2). This indicates that some autoreactive T cells directed against membrane antigens present on bone marrow-derived cells and also expressed in the thymus are not necessarily eliminated by intrathymic deletion.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8822934

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

Review 1.  Piecing together the humoral and cellular mechanisms of immune thrombocytopenia.

Authors:  Lisa J Toltl; Ishac Nazi; Reza Jafari; Donald M Arnold
Journal:  Semin Thromb Hemost       Date:  2011-11-18       Impact factor: 4.180

2.  Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura.

Authors:  Jin Yu; Susanne Heck; Vivek Patel; Jared Levan; Yu Yu; James B Bussel; Karina Yazdanbakhsh
Journal:  Blood       Date:  2008-04-17       Impact factor: 22.113

Review 3.  Pathophysiology and therapeutic options in primary immune thrombocytopenia.

Authors:  Roberto Stasi
Journal:  Blood Transfus       Date:  2010-11-26       Impact factor: 3.443

4.  Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents.

Authors:  Weili Bao; James B Bussel; Susanne Heck; Wu He; Marissa Karpoff; Nayla Boulad; Karina Yazdanbakhsh
Journal:  Blood       Date:  2010-08-05       Impact factor: 22.113

Review 5.  The role of autoreactive T-cells in the pathogenesis of idiopathic thrombocytopenic purpura.

Authors:  Masataka Kuwana; Yasuo Ikeda
Journal:  Int J Hematol       Date:  2005-02       Impact factor: 2.490

6.  Survival of autoreactive T lymphocytes by microRNA-mediated regulation of apoptosis through TRAIL and Fas in type 1 diabetes.

Authors:  V M de Jong; A R van der Slik; S Laban; R van 't Slot; B P C Koeleman; A Zaldumbide; B O Roep
Journal:  Genes Immun       Date:  2016-07-28       Impact factor: 2.676

7.  Idiopathic thrombocytopenic purpura: better therapeutic responses of patients with B- or T-cell clonality than patients without clonality.

Authors:  J Kim; C J Park; H S Chi; M J Kim; J J Seo; H N Moon; T T Ghim; S W Kim; J H Lee; G H Lee; J S Lee
Journal:  Int J Hematol       Date:  2003-12       Impact factor: 2.490

8.  Autoreactive T cells to platelet GPIIb-IIIa in immune thrombocytopenic purpura. Role in production of anti-platelet autoantibody.

Authors:  M Kuwana; J Kaburaki; Y Ikeda
Journal:  J Clin Invest       Date:  1998-10-01       Impact factor: 14.808

9.  Imbalanced immune homeostasis in immune thrombocytopenia.

Authors:  Karina Yazdanbakhsh
Journal:  Semin Hematol       Date:  2016-04-07       Impact factor: 3.851

10.  Lenalidomide-Associated ITP.

Authors:  Christina I Herold; Cristina Gasparetto; Gowthami M Arepally
Journal:  Case Rep Hematol       Date:  2011-07-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.